This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Novo Nordisk A/s. Active years: 2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013
Title: Johan Karlsson: Innovating Factor VIII Purification
Introduction
Johan Karlsson, an accomplished inventor based in Skurup, Sweden, has made a significant contribution to the field of biochemistry with his innovative approach to protein purification. His work primarily focuses on improving the efficiency and effectiveness of the purification process for crucial recombinant proteins, particularly coagulation factors.
Latest Patents
Karlsson holds a patent for the "Purification of factor VIII using a mixed-mode or multimodal resin." This invention outlines a groundbreaking method for purifying recombinant proteins utilizing a multimodal resin that incorporates ligands with both hydrophobic and negatively charged components. The method is particularly notable for being a single-step chromatographic process that eliminates the need for pH or conductivity adjustment during the loading phase. As a result, this innovative approach achieves high yield and potency in the purification of recombinant Factor VIII.
Career Highlights
Currently, Johan Karlsson is employed at Novo Nordisk A/S, a leading global healthcare company known for its commitment to diabetes care and innovative biopharmaceuticals. His work at Novo Nordisk emphasizes the importance of developing advanced therapeutic solutions and contributes to the company's reputation for innovation in the pharmaceutical industry.
Collaborations
Throughout his career, Karlsson has collaborated with talented colleagues, including Susanne Bang and Lars Thim. These partnerships foster a creative and innovative work environment, allowing for the exchange of ideas and expertise in the pursuit of advancement in biopharmaceutical technologies.
Conclusion
Johan Karlsson's contributions to the purification of recombinant proteins represent a valuable advancement in biotechnology. His inventive solutions not only enhance the purity and effectiveness of critical coagulation factors but also reflect the spirit of innovation that drives progress in the biopharmaceutical field. With his ongoing work at Novo Nordisk and collaborations with esteemed colleagues, Karlsson continues to play a pivotal role in shaping the future of medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile